Analysis of clinical characteristics and prognosis of 13 cases of acute erythroleukemia.
10.7534/j.issn.1009-2137.2013.05.011
- Author:
Yue-Lu GUO
1
;
Min-Hang ZHOU
;
Ting-Ting CAO
;
Li-Ping DOU
;
Xiao-Lin LU
;
Qian-Fei ZHANG
;
Zi-Long YAO
;
Li-Li WANG
;
Li YU
;
Yu JING
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Child;
Child, Preschool;
Female;
Humans;
Karyotyping;
Leukemia, Erythroblastic, Acute;
diagnosis;
genetics;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Survival Rate;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(5):1142-1147
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the clinical characteristics and prognosis of acute erythroleukemia (AEL, AML-M6). The clinical features and results of morphologic, immunophenotypic, cytogenetic and molecular biologic detections were retrospectively analyzed in 13 cases of AEL from 305 acute leukemia patients hospitalized between October 2007 and October 2012. The results showed that the expression of erythroid and non-erythroid cells increased at the same time. The myeloid antigens mainly expressed CD13/CD33/CD117/CD34, while the erythroid antigens expressed Gly and CD71. The karyotypic detection indicated that there were 1 case with normal karyotype, 3 cases with simple karyotypic abnormality and 2 cases with complex karyotypic abnormality, the other cases were not detected. The molecular biological detection found that the poor prognosis gene existed in 5 cases [38.5% (5/13)], including 3 cases with MLL-MLL fusion gene, 1 case with MLL mutation, and 1 cases with NRAS gene mutation, the abnormal genes were not detected in remainder 8 cases. After chemotherapy with decitabine, the complete remission (CR) rate achieved 53.5% (7/13), partial remission (DR) rate achieved 15.4% (2/13). Finally, 8 patients received allo-HSCT, the median overall survival (OS) was 20.7 months, 3 year survival rate was 79%, 3 year disease-free survival rate was 78%. It is concluded that the acute erythroleukemia is a rare subtype of AML, which is transformed from MDS and has harmful genes and poor prognosis. Allo-HSCT and treatment with decitabine may enhance the survival rate of AEL.
